The US Food and Drug Administration has given the green light to Roche for its FoundationOne CDx personalised diagnostic cancer test, the Swiss group said Monday.
Roche said the FDA had approved the test helping doctors understand the genetic profile of patients' tumors to enable better-targeted therapies and clinical tests.
"The approval of FoundationOne CDx represents a major advance in the personalisation of cancer care, facilitating access for patients in the US to a comprehensive pan-tumour companion diagnostic that will help identify approved treatment options based on the molecular footprint of each individual’s cancer," said Roche's Chief Medical Officer Sandra Horning, also the firm's head of global product development.
"Our belief is that profiling will increasingly become routine in clinical practice, so we have worked closely with Foundation Medicine to develop an extensive clinically and analytically validated platform that can support both existing and future companion diagnostic needs," Horning said in a statement.
Pharmaceutical companies see development of personally tailored treatment as the way ahead to tackle cancer
GMT 22:42 2018 Thursday ,13 December
'World of Food Abu Dhabi' kicks off at Umm Al Emarat ParkGMT 14:21 2018 Monday ,26 November
Pandora's Box': Chinese scientists condemn human gene-editing claimGMT 10:45 2018 Thursday ,15 November
Major genes-focused testing for Aussies points to better treatment of rare cancersGMT 13:27 2018 Friday ,09 November
Marathon to support children with cancer kicks off in DamascusGMT 16:12 2018 Tuesday ,06 November
SARC carries out vaccination campaign for children in al-Rakban campGMT 13:02 2018 Tuesday ,30 October
Greenhouse facility for self-sufficient food production opens in Al AinGMT 07:02 2018 Wednesday ,24 October
Viral outbreak kills six children and left 12 more sick at New Jersey rehab centreGMT 11:17 2018 Sunday ,21 October
Egypt health minister discusses boosting cooperation with Ethiopian health delegationMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor